Advancing Clinical Trials and Decision-Making With Synthetic Real-World Data
Eddy Saad, MD, MS, explains how synthetic real-world datasets could be used to accelerate cancer research while protecting the privacy of patient data.
My Work
3D Vision–Language Foundation Model Interprets Abdominal CT Scans, May Improve Clinical Assessment
A 3D vision–language foundation model trained to interpret abdominal computed tomography (CT) scans may help expedite clinical assessment, including diagnosis, staging, and other aspects of care. Beyond disease identification and classification, the multimodal model—named Merlin—also demonstrated potential for biomarker discovery and disease risk stratification using CT imaging.
Consumer-Facing LLM ChatGPT Health Falls Short in Several High-Risk Triage Scenarios
Researchers conducted a structured stress test of ChatGPT Health’s triage abilities and recommendations, identifying dangerous failures and missed high-risk emergencies by the large language model across multiple urgent medical situations.
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published in the Journal of Clinical Oncology.
Are AI Tools in Pathology Learning True Biomarker Signals or Statistical Shortcuts?
Tools designed to detect molecular biomarker status from histologic images using AI may be more dependent upon correlational relationships with clinicopathologic features than on causal signals of the biomarker.
Oncology Societies Answer HHS RFI on AI Use in Clinical Care
The Department of Health and Human Services (HHS) completed a request for information from stakeholders on advancing the adoption and use of AI in clinical care. Multiple oncology-focused organizations submitted responses outlining priorities for AI oversight and integration.
Clinical Staff Using Natural Language Processing Model Enhances Accuracy of Clinical Trial Prescreening Process
A randomized, noninferiority trial demonstrated that when trained research staff use a pretrained language model for assistance in prescreening patients for enrollment in a clinical trial, the AI can boost the accuracy and efficiency of the eligibility criteria assessment.
AI-Selected Predictive Biomarker Guides First-Line Treatment Selection in Advanced Pancreatic Cancer
A computational histology–based artificial intelligence (AI) platform was able to identify a biomarker that could predict treatment benefit between two chemotherapy options for patients with advanced pancreatic cancer, according to the results of a study presented in a poster at the 2026 ASCO Gastrointestinal Cancers Symposium.A computational histology–based artificial intelligence (AI) platform was able to identify a biomarker that could predict treatment benefit between two chemotherapy option...
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the risk of brain metastases.
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy.
Findings from the De-Squamate study were published in the Journal of Clinical Oncology.
Findings from the De-Squamate study were published in the Journal of Clinical Oncology.
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings presented during the inaugural European Society for Medical Oncology (ESMO) AI & Digital Oncology Congress.
Toxicity Concerns for PARP Inhibition Given Concurrently With Adjuvant Radiotherapy for Breast Cancer
Rates of radiotherapy-associated adverse events were considerably higher with the concurrent addition of low doses of the PARP inhibitor olaparib compared with radiotherapy alone in patients with inflammatory breast cancer in the adjuvant setting, according to the results of a toxicity analysis from the SWOG 1706 trial prior to maturing efficacy findings.
Safety and Benefit of Radiation Therapy for High-Risk Muscle-Invasive Bladder Cancer
Findings from the phase III BART trial presented in a plenary session during the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting may assuage concerns over radiotherapy to the pelvis after cystectomy and provide an improvement over chemotherapy for locoregional recurrences.
PARP Inhibition Plus Abiraterone Shows Benefit in HRR-Altered Metastatic Castration-Sensitive Prostate Cancer
Use of the PARP inhibitor niraparib in combination with the androgen biosynthesis inhibitor abiraterone acetate and the corticosteroid prednisone reduced the risk of disease progression, both radiographic and symptomatic, in patients with metastatic castration-sensitive prostate cancer harboring alterations in homologous recombination repair (HRR) genes, according to findings from the phase III AMPLITUDE trial.
Alcohol-Associated Cancer Death Rates Are Climbing
Alcohol-associated cancer deaths have doubled in the United States, disproportionately affecting men and those aged 55 or older, according to the results of an observational study presented at the 2025 ASCO Annual Meeting.
Evidence of Potential Cure With Single CAR T-Cell Infusion for Some Patients With Multiple Myeloma
In long-term results from the CARTITUDE-1 trial, investigators had found that the autologous cellular immunotherapy ciltacabtagene autoleucel was potentially curative for one-third of patients with heavily pretreated relapsed or refractory multiple myeloma. These patients remained progression-free for at least 5 years after a single infusion of ciltacabtagene autoleucel without any subsequent or maintenance treatment.
In Second-Line Setting, T-DXd Improves Survival Outcomes in HER2-Positive Gastric or Gastroesophageal Junction Cancer
In the phase III DESTINY-Gastric04 trial, use of the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was compared head to head with the monoclonal antibody ramucirumab and paclitaxel in patients with previously treated, HER2-positive metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Guiding Material Selection in All-on-X Restorations
All-on-X implants revolutionized prosthetic dentistry, providing patients with a strong and remarkably natural-looking fixed full-arch prosthetic that can last for many years.
"The All-on-X treatment is the pinnacle of replacement dentistry," says Harshit Aggarwal, MSD, prosthodontist, Center for Dentofacial Aesthetics, Annandale, Virginia. "Nothing else we have available now is better or closer to what Mother Nature gave us in terms of replacements."...
"The All-on-X treatment is the pinnacle of replacement dentistry," says Harshit Aggarwal, MSD, prosthodontist, Center for Dentofacial Aesthetics, Annandale, Virginia. "Nothing else we have available now is better or closer to what Mother Nature gave us in terms of replacements."...
Women Shaping the Dental Lab Field
Meet the women who are driving change and empowering the next generation of leaders in the dental laboratory field.
Riding the Wave of Chemoimmunotherapy: A New Era in Endometrial Cancer Management
According to Brian Slomovitz, MD, “immunotherapy has activity and [provides] a benefit in all women with endometrial cancer.” Slomovitz, division director of gynecologic oncology at Mount Sinai Medical Center, professor of obstetrics and gynecology at Florida International University, and clinical trial lead for uterine cancers at the GOG Foundation, told Targeted Therapies in Oncology that especially for patients with deficient mismatch repair (dMMR) endometrial tumors, immunotherapy has result...
Emerging Frontiers in Immunotherapy: The Promise of NK-Cell Therapies
The landscape of cancer therapy has been witnessing a paradigm shift with the advent of immunotherapy treatments, especially for patients with hematologic malignancies. This special feature explores a novel immunotherapy approach for treating patients with cancer.
Groundbreaking ADCs Are Expanding to New Settings for More Patients With Breast Cancer
Presenters at the 2022 San Antonio Breast Cancer Symposium discussed how antibody-drug conjugates have been changing the treatment landscape for patients with breast cancer.
Despite Shortcomings, Key Learnings Gleaned From Phase 3 Trials
Oncologists often anticipate the results of large, randomized phase 3 clinical trials to learn how they might affect the oncology treatment landscape going forward. Not all studies, however, have an immediate practice-changing impact.Several studies with data released or presented in 2022 did not meet the threshold for significance or achieve their primary end points. Although such results are disappointing, takeaways from the trials can be used by the field as a whole to improve clinical trial...
New HER2-Low Subgroup Expands Utility of HER2-Targeted Therapies
One of the biggest shifts in the oncology field from the past year was the introduction of HER2-low into clinical practice. Patients with breast cancer have typically been divided by subtype according to HER2 positivity or negativity, but emerging evidence suggests that there is now room and treatment options available for a third group of patients that was previously ignored, those characterized with HER2-low disease.HER2 positivity is considered overexpression of HER2 as assessed by an immunoh...
Load More
